BioSpace News Archive

-- Jorge Ruiz, M.D., Associate Director for Clinical Affairs, Geriatric Research at the Miami VA Healthcare System, will present Longeveron’s Aging Frailty Phase 2b Trial Data

Fauna Bio today announced it has raised $9 million in Seed funding led by LifeForce Capital, with participation from True Ventures, Boom Capital, Pacific 8 Ventures, BioMed Ventures, Vibe Capital and Arcadia Science.

Viridian Therapeutics, Inc., a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by ‘s therapies, today announced the pricing of an underwritten public offering with gross proceeds of approximately $85.0 million.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces further extension of the global footprint of Maxigesic® IV, a novel, unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatment of post-operative pain.

Gelatin capsules, often known as gel caps or gelcaps, are made of gelatin derived from animal skin or bone collagen. Gelatin, a pure protein, is tasteless, gluten-free, and GMO-free, and it provides a safe oral dose form that provides customers a pleasant experience.

Chronic focal encephalitis (CFE) is an uncommon but deadly inflammatory brain illness in which individuals fight their own immune system.

CorWave, a French medtech developing a next-generation heart pump, is recruiting top talent from throughout the world to strengthen its team.

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced that the Company and its collaborators have published a new research article presenting clinical data demonstrating disease modification in knee osteoarthritis patients treated with TPX-100, the Company’s leading candidate for a Disease Modifying Osteoarthritis Drug.

Orthofix Medical Inc today announced the full market launch of the Opus ™ Mg Set osteoconductive scaffold, a synthetic magnesium-based bone void filler for orthopedic procedures.

VectivBio Holding AG, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced the closing of its previously announced acquisition of Comet Therapeutics, Inc., a privately held company that has been developing drugs to address previously untreatable Inherited Metabolic Diseases.